Article
Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance.
Cancer research - 1 Jan 2009
Ihle Nathan T, Lemos Robert, Wipf Peter, Yacoub Adly, Mitchell Clint, Siwak Doris, Mills Gordon B, Dent Paul, Kirkpatrick D Lynn, Powis Garth
Abstract excerpt
The novel phosphatidylinositol-3-kinase (PI3K) inhibitor PX-866 was tested against 13 experimental human tumor xenografts derived from cell lines of various tissue origins. Mutant PI3K (PIK3CA) and loss of PTEN activity were sufficient, but not necessary, as predictors of sensitivity to the antit...
Topics
- Animals
- Apoptosis
- Cell Line, Transformed
- Cell Line, Tumor
- Drug Resistance, Neoplasm
- Genes, ras
- Gonanes
- Humans
- Mice
- Mice, SCID
- Mutation
- Neoplasms
- PTEN Phosphohydrolase
- Phosphatidylinositol 3-Kinases